Bris­tol-My­ers makes a de­ci­sive move to fix its R&D prob­lem; Let's not un­der­es­ti­mate Trump now

End­points as­sess­es the big bio­phar­ma sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Bris­tol-My­ers steps up to fix a de­railed R&D or­ga­ni­za­tion. But ques­tions linger

No big bio­phar­ma has suf­fered a big­ger set­back than Bris­tol-My­ers Squibb’s back­ward march on Op­di­vo. Over­reach­ing in lung can­cer, they have for­feit­ed their lead role on one of the biggest new drug fran­chis­es in the in­dus­try. In a busi­ness where not screw­ing up is half the game, they blew it. And this is a com­pa­ny that has had one of the most in­no­v­a­tive and pro­duc­tive R&D op­er­a­tions of the past decade.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.